Comparing four different ALK antibodies with manual immunohistochemistry (IHC) to screen for ALK-rearranged non-small cell lung cancer (NSCLC)

Lung Cancer

Volumn 90, Issue 3, 2015, Pages 492-498

  Shen, Qin ^a   Wang, Xuan ^a   Yu, Bo ^a   Shi, Shanshan ^a   Liu, Biao ^a   Wang, Yanfen ^a   Xia, Qiuyuan ^a   Rao, Qiu ^a   Zhou, Xiaojun ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Anaplastic lymphoma kinase (ALK) gene rearrangement; Antibody 1A4 1H7; Immunohistochemistry (IHC); Non small cell lung cancer (NSCLC)

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANAPLASTIC LYMPHOMA KINASE ANTIBODY; ENZYME ANTIBODY; MONOCLONAL ANTIBODY 1A4 1H7; MONOCLONAL ANTIBODY 5A4; MONOCLONAL ANTIBODY D5F3; UNCLASSIFIED DRUG; PROTEIN TYROSINE KINASE;

ADULT; ARTICLE; CANCER CELL; CANCER DIAGNOSIS; CANCER STAGING; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; LUNG NEOPLASMS; METABOLISM;

CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84949185975     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.10.002     Document Type: Article

References (37)

1. Soda M., Choi Y.L., Enomoto M., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
2. Selinger C.I., Rogers T.M., Russell P.A., et al. Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod. Pathol. 2013, 26:1545-1553.
3. Kwak E.L., Bang Y.J., Camidge D.R., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 2010, 363:1693-1703.
4. Shackelford R.E., Vora M., Mayhall K., et al. ALK-rearrangements and testing methods in non-small cell lung cancer: a review. Genes Cancer 2014, 5:1-14.
5. Gorczynski A., Prelowska M., Adam P., et al. ALK-positive cancer: still a growing entity. Future Oncol. 2014, 10:305-321.
6. Kerr K.M., Bubendorf L., Edelman M.J., et al. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Ann. Oncol. 2014, 25:1681-1690.
7. Lindeman N.I., Cagle P.T., Beasley M.B., et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors. J. Thorac. Oncol. 2013, 8:823-859.
8. Zhou J., Zhao J., Sun K., et al. Accurate and economical detection of ALK positive lung adenocarcinoma with semiquantitative immunohistochemical screening. PLoS One 2014, 9:e92828.
9. Camidge D.R., Kono S.A., Flacco A., et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin. Cancer Res. 2010, 16:5581-5590.
10. Palmer R.H., Vernersson E., Grabbe C., et al. Anaplastic lymphoma kinase: signalling in development and disease. Biochem. J. 2009, 420:345-361.
11. Minca E.C., Portier B.P., Wang Z., et al. ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH. J. Mol. Diagn. 2013, 15:341-346.
12. Ying J., Guo L., Qiu T., et al. Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma. Ann. Oncol. 2013, 24:2589-2593.
13. Rossi G., Ragazzi M., Tamagnini I., et al. Does immunohistochemistry represent a robust alternative technique in determining drugable predictive gene alterations in non-small cell lung cancer?. Curr. Drug Targets 2015.
14. Hutarew G., Hauser-Kronberger C., Strasser F., et al. Immunohistochemistry as a screening tool for ALK rearrangement in NSCLC: evaluation of five different ALK antibody clones and ALKFISH. Histopathology 2014, 65:398-407.
15. Yi E.S., Tang H., Stoddard S., et al. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J. Thorac. Oncol. 2011, 6:459.
16. X.C. Zhang, S. Lu, L. Zhang, et al., Consensus on dignosis for ALK positive non-small cell lung cancer in china, the 2013 version, Zhonghua Bing Li Xue Za Zhi, 6, 402-406 (2013).
17. Desai S.S., Shah A.S., Prabhash K., et al. A year of anaplastic large cell kinase testing for lung carcinoma: pathological and technical perspectives. Indian J. Cancer 2013, 50:80.
18. Houang M., Toon C.W., Clarkson A., et al. Reflex ALK immunohistochemistry is feasible and highly specific for ALK gene rearrangements in lung cancer. Pathology 2014, 46:383-388.
19. Mino-Kenudson M., Chirieac L.R., Law K., et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin. Cancer Res. 2010, 16:1561-1571.
20. Abe H., Kawahara A., Azuma K., et al. Heterogeneity of anaplastic lymphoma kinase gene rearrangement in non-small-cell lung carcinomas. J. Thorac. Oncol. 2015, 10:800-805.
21. Ying J., Guo L., Qiu T., et al. Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma. Ann. Oncol. 2013, 24:2589-2593.
22. Sholl L.M. Protein correlates of molecular alterations in lung adenocarcinoma: immunohistochemistry as a surrogate for molecular analysis. Semin. Diagn. Pathol. 2015.
23. Li Y., Pan Y., Wang R., et al. ALK-rearranged lung cancer in Chinese: a comprehensive assessment of clinicopathology, IHC, FISH and RT-PCR. PLoS One 2013, 8:e69016.
24. Fu S., Wang F., Shao Q., et al. Detection of EML4-ALK fusion gene in Chinese non-small cell lung cancer by using a sensitive quantitative real-time reverse transcriptase PCR technique. Appl. Immunohistochem. Mol. Morphol. 2015, 23:245-254.
25. Blackhall F.H., Peters S., Bubendorf L., et al. Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the european thoracic oncology platform lungscape project. J. Clin. Oncol. 2014, 32:2780-2787.
26. McLeer-Florin A., Moro-Sibilot D., Melis A., et al. Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study. J. Thorac. Oncol. 2012, 7:348-354.
27. Paik J.H., Choe G., Kim H., et al. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J. Thorac. Oncol. 2011, 6:466.
28. Zwaenepoel K., Van Dongen A., Lambin S., et al. Detection of ALK expression in non-small-cell lung cancer with ALK gene rearrangements-comparison of multiple immunohistochemical methods. Histopathology 2014, 65:539-548.
29. Conklin C.M., Craddock K.J., Have C., et al. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. J. Thorac. Oncol. 2013, 8:45-51.
30. Cabillic F., Gros A., Dugay F., et al. Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances. J. Thorac. Oncol. 2014, 9:295-306.
31. Conde E., Ana S.R., Amparo B. Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry. PLoS One 2014, 9:e107200.
32. Le Q., uesne J., Maurya M., Yancheva S.G., et al. A comparison of immunohistochemical assays and FISH in detecting the ALK translocation in diagnostic histological and cytological lung tumor material. J. Thorac. Oncol. 2014, 9:769-774.
33. Savic S., Diebold J., Zimmermann A., et al. Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended. Lung Cancer 2015.
34. Gruber K., Kohlhäufl M., Friedel G., et al. A novel, highly sensitive ALK antibody 1A4 facilitates effective screening for ALK rearrangements in lung adenocarcinomas by standard immunohistochemistry. J. Thorac. Oncol. 2015, 10:713-716.
35. E. Thunnissen, L. Bubendorf, M. Dietel, et al., EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations, In, vol. 461, 245-257 (2012).
36. Lindeman N.I., Cagle P.T., Beasley M.B., et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J. Mol. Diagn. 2013, 15:415-453.
37. Alì G., Proietti A., Niccoli C., et al. EML4-ALK translocation in both metachronous second primary lung sarcomatoid carcinoma and lung adenocarcinoma: a case report. Lung Cancer 2013, 81:297-301.